Analysts’ Viewpoint
Acute migraine treatment is a growing industry, with the availability of a wide range of medications and therapies. These include over-the-counter (OTC) pain relievers such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) as well as prescription medications such as triptans, ergotamines, and opioids.
The global acute migraine treatment market size is expected to experience significant growth in the next few years. This can be ascribed to the rise in prevalence of migraine, development of new & more effective treatments, and surge in geriatric population.
Introduction of effective and low-cost treatments for migraine is creating significant opportunities for the industry. Manufacturers are investing significantly in R&D activities for the development of advanced medications and therapies for migraines.
Migraine is a common disabling neurological condition that significantly impacts the patient's quality of life. It is defined as a chronic disorder characterized by headaches. Migraines can be severe and debilitating, and can interfere with a person's daily activities.
Different types of migraine are migraines with aura, migraines without aura, and chronic migraines. Migraine can be treated with medications and lifestyle changes such as getting enough sleep, eating a healthy diet, and reducing stress.
Surge in awareness about the impact of migraine on quality of life is driving the demand for treatment options that can help alleviate the symptoms of a migraine attack. Rise in awareness about migraine could also lead to changes in societal attitudes toward the condition, with a greater understanding of the impact of migraine on daily life and a recognition of the need for effective treatment options.
According to World Health Organization data, the global prevalence of migraine is estimated to be around 14%, with around 1 billion people affected across the world. Increase in awareness about the condition is likely to boost the demand for these treatments.
Furthermore, rise in focus on research & development in the pharmaceutical industry has led to the introduction of new and more effective treatments for migraine such as abortive therapy of migraine and symptomatic therapy of migraine.
Migraine is a leading cause of disability across the globe. It is ranked as the seventh largest cause of disability across the globe and the second largest cause of disability among women. The impact of migraine on the quality of life and work productivity can be significant.
This is driving the demand for effective treatment options.The prevalence of migraine increases with age; the condition is becoming more common in people aged above 50. The prevalence of migraine is estimated to be around 12% in the U.S., with around 36 million people affected by the condition.
It is more common in women than in men, with an estimated 18% of women experiencing the condition.The prevalence of migraine in Europe is around 10% to 15%, with around 50 million people affected by the condition.
The prevalence of migraine is estimated to be around 13% in the U.K., with approximately 8 million people affected by the condition. Thus, rise in prevalence of migraine is a key driver of the global acute migraine treatment market.
Based on drug type, the CGRP antagonist segment is likely to account for the largest global market share during the forecast period. CGRP antagonist works by blocking the action of CGRP, a chemical that is involved in the development of migraine.
CGRP antagonists are effective for the treatment of acute migraine and are being investigated as a potential preventive treatment for the condition. The CGRP antagonists segment is expected to be driven by rise in prevalence of migraine and surge in demand for effective and convenient treatment options.
Based on route of administration, the oral segment is anticipated to hold significant share of the global acute migraine treatment market during the forecast period.
Oral medications are generally considered convenient and easy to use, and are often the first line of treatment for migraine. In addition to medication, other treatment options, such as lifestyle modifications and preventive medications, may be recommended to help reduce the frequency and severity of migraines.
North America held the largest share of around 40.0% of the industry in 2021. The region is expected to record substantial market progress during the forecast period. North America's global dominance can be ascribed to the increase in incidence of migraine in the region.
The U.S. dominated market development in North America owing to factors such as presence of global players and increase in research & development activities in migraine treatment.
As per acute migraine treatment market trends, Asia Pacific is projected to be the fastest growing region during the forecast period. The market in the region is anticipated to expand at a high CAGR from 2022 to 2031 due to increase in population.
The global acute migraine treatment market is fragmented, with the presence of large number of players. Companies are investing significantly in research & development activities, primarily to develop innovative products. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the key players in the market.
Teva Pharmaceutical, Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen, AstraZeneca, Pfizer, Inc., Merck & Co., Novartis AG, Allergan plc, BioDelivery Sciences International, Inc., AbbVie, and Eli Lilly and Company are the prominent companies operating in the sector.
Each of these players has been profiled in the acute migraine treatment market report based on parameters such as company overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Size in 2021 |
US$ 2.1 Bn |
|
Forecast (Value) in 2031 |
More than US$ 7.9 Bn |
|
Growth Rate (CAGR) |
15.1% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global industry was valued at US$ 2.1 Bn in 2021
It is projected to reach more than US$ 7.9 Bn by 2031
The CAGR is expected to be 15.1% from 2022 to 2031
Increase in awareness about acute migraine and rise in prevalence of migraine
North America is likely to account for significant share during the forecast period
Teva Pharmaceutical, Hoffmann-La Roche Ltd., Johnson and Johnson, Amgen, AstraZeneca, Pfizer Inc., Merck & Co., Novartis AG, Allergan plc, BioDelivery Sciences International, Inc., AbbVie, and Eli Lilly and Company
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Acute Migraine Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Acute Migraine Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Key Industry Events
5.2. Pipeline Analysis
5.3. Regulatory Scenario by Region/Globally
5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Acute Migraine Treatment Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2017–2031
6.3.1. Triptans
6.3.2. CGRP Antagonist
6.3.3. NSAID Drugs
6.3.4. Beta-adrenergic Blockers
6.3.5. Ergot Alkaloids
6.3.6. Others
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Acute Migraine Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Injection
7.3.3. Others
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Acute Migraine Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Acute Migraine Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Acute Migraine Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Type, 2017–2031
10.2.1. Triptans
10.2.2. CGRP Antagonist
10.2.3. NSAID Drugs
10.2.4. Beta-adrenergic Blockers
10.2.5. Ergot Alkaloids
10.2.6. Others
10.3. Market Value Forecast, by Route of Administration, 2017–2031
10.3.1. Oral
10.3.2. Injection
10.3.3. Others
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Type
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Acute Migraine Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2017–2031
11.2.1. Triptans
11.2.2. CGRP Antagonist
11.2.3. NSAID Drugs
11.2.4. Beta-adrenergic Blockers
11.2.5. Ergot Alkaloids
11.2.6. Others
11.3. Market Value Forecast, by Route of Administration, 2017–2031
11.3.1. Oral
11.3.2. Injection
11.3.3. Others
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Type
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Acute Migraine Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2017–2031
12.2.1. Triptans
12.2.2. CGRP Antagonist
12.2.3. NSAID Drugs
12.2.4. Beta-adrenergic Blockers
12.2.5. Ergot Alkaloids
12.2.6. Others
12.3. Market Value Forecast, by Route of Administration, 2017–2031
12.3.1. Oral
12.3.2. Injection
12.3.3. Others
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Type
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Acute Migraine Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2017–2031
13.2.1. Triptans
13.2.2. CGRP Antagonist
13.2.3. NSAID Drugs
13.2.4. Beta-adrenergic Blockers
13.2.5. Ergot Alkaloids
13.2.6. Others
13.3. Market Value Forecast, by Route of Administration, 2017–2031
13.3.1. Oral
13.3.2. Injection
13.3.3. Others
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Type
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Acute Migraine Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Type, 2017–2031
14.2.1. Triptans
14.2.2. CGRP Antagonist
14.2.3. NSAID Drugs
14.2.4. Beta-adrenergic Blockers
14.2.5. Ergot Alkaloids
14.2.6. Others
14.3. Market Value Forecast, by Route of Administration, 2017–2031
14.3.1. Oral
14.3.2. Injection
14.3.3. Others
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Type
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company (2021)
15.3. Company Profiles
15.3.1. Teva Pharmaceutical
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Hoffmann-La Roche Ltd.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Johnson and Johnson
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Amgen
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. AstraZeneca
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.6. Pfizer, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.7. Merck & Co.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.8. Novartis AG
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.9. Allergan plc
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.10. Eli Lilly and Company
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.11. AbbVie
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.12. BioDelivery Sciences International, Inc.
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Product Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
List of Tables
Table 01: Global Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 02: Global Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 03: Global Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 06: North America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 07: North America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 08: North America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 09: Europe Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 10: Europe Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 11: Europe Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 12: Europe Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Asia Pacific Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 14: Asia Pacific Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 15: Asia Pacific Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Asia Pacific Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Latin America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 18: Latin America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 19: Latin America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 20: Latin America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 21: Middle East & Africa Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 22: Middle East & Africa Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 23: Middle East & Africa Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 24: Middle East & Africa Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Acute Migraine Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Acute Migraine Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 03: Global Acute Migraine Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 04: Global Acute Migraine Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 05: Global Acute Migraine Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 06: Global Acute Migraine Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 07: Global Acute Migraine Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 08: Global Acute Migraine Treatment Market Value Share Analysis, by Region, 2021 and 2031
Figure 09: Global Acute Migraine Treatment Market Attractiveness Analysis, by Region, 2022–2031
Figure 10: North America Acute Migraine Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 11: North America Acute Migraine Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 12: North America Acute Migraine Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 13: North America Acute Migraine Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 14: North America Acute Migraine Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 15: North America Acute Migraine Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 16: North America Acute Migraine Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 17: North America Acute Migraine Treatment Market Value Share Analysis, by Country, 2021 and 2031
Figure 18: North America Acute Migraine Treatment Market Attractiveness Analysis, by Country, 2022–2031
Figure 19: Europe Acute Migraine Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 20: Europe Acute Migraine Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 21: Europe Acute Migraine Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 22: Europe Acute Migraine Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 23: Europe Acute Migraine Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 24: Europe Acute Migraine Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 25: Europe Acute Migraine Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 26: Europe Acute Migraine Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 27: Europe Acute Migraine Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 28: Asia Pacific Acute Migraine Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 29: Asia Pacific Acute Migraine Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 30: Asia Pacific Acute Migraine Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 31: Asia Pacific Acute Migraine Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 32: Asia Pacific Acute Migraine Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 33: Asia Pacific Acute Migraine Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 34: Asia Pacific Acute Migraine Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 35: Asia Pacific Acute Migraine Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 36: Asia Pacific Acute Migraine Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 37: Latin America Acute Migraine Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 38: Latin America Acute Migraine Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 39: Latin America Acute Migraine Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 40: Latin America Acute Migraine Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 41: Latin America Acute Migraine Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 42: Latin America Acute Migraine Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 43: Latin America Acute Migraine Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 44: Latin America Acute Migraine Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 45: Latin America Acute Migraine Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 46: Middle East & Africa Acute Migraine Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 47: Middle East & Africa Acute Migraine Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 48: Middle East & Africa Acute Migraine Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 49: Middle East & Africa Acute Migraine Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 50: Middle East & Africa Acute Migraine Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 51: Middle East & Africa Acute Migraine Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 52: Middle East & Africa Acute Migraine Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 53: Middle East & Africa Acute Migraine Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 54: Middle East & Africa Acute Migraine Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 55: Global Acute Migraine Treatment Market Share Analysis, by Company, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Acute Migraine Treatment Market
